Effects of hyperglycemia on oxygenation, radiosensitivity and bioenergetic status of subcutaneous RIF-1 tumors.
Since tissue oxygen tension is a balance between delivery and consumption of oxygen, considerable effort has been directed at increasing the former and/or decreasing the latter. Techniques to decrease the rate of cellular oxygen consumption (increasing the distance oxygen can diffuse into tissues) include increasing glycolysis by administering supra-physiologic levels of glucose. We have examined the effect of hyperglycemia produced by intravenous glucose infusion on the tissue oxygenation and radiation response of subcutaneously implanted murine radiation induced fibrosarcomas (RIF-1). A 0.3 M glucose solution was delivered via tail vein injection according to a protocol that maintained glucose at a plasma concentration of 17+/-1 mM. The effect of this treatment on radiation response (clonogenic and growth delay studies), tumor oxygenation (needle electrode pO2 and 2-[2-nitro-1H-imidazol-1-yl]-N-(2,2,3,3,3-pentafluoropropyl) acetamide (EF5) binding), and tumor bioenergetics and pH (31P NMR spectroscopy) was examined. Systemic measurements included hematocrit and blood glucose and lactate concentrations. The results of these studies suggest that these subcutaneously implanted RIF-1 tumors are both radiobiologically and metabolically hypoxic and that intravenous glucose infusion is not an effective method of modifying this metabolic state.
Nadal-Desbarats
L
L
Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA.
Poptani
H
H
Oprysko
P
P
Jenkins
W T
WT
Busch
T M
TM
Nelson
D S
DS
Glickson
J D
JD
Koch
C J
CJ
Evans
S M
SM
D000818:Animals; D002455:Cell Division; D004734:Energy Metabolism; D017341:Etanidazole / Q000031:analogs & derivatives* / Q000494:pharmacology; D005260:Female; D005354:Fibrosarcoma / Q000378:metabolism* / Q000532:radiotherapy; D005434:Flow Cytometry; D005947:Glucose / Q000378:metabolism* / Q000494:pharmacology; D006400:Hematocrit; D006845:Hydrocarbons, Fluorinated / Q000494:pharmacology; D006943:Hyperglycemia / Q000378:metabolism*; D009682:Magnetic Resonance Spectroscopy / Q000379:methods; D051379:Mice; D008809:Mice, Inbred C3H; D009368:Neoplasm Transplantation; D009381:Neoplasms, Radiation-Induced / Q000378:metabolism*; D010101:Oxygen Consumption; D011836:Radiation Tolerance; D011838:Radiation-Sensitizing Agents / Q000494:pharmacology; D012513:Sarcoma, Experimental / Q000378:metabolism* / Q000532:radiotherapy; D015996:Survival Rate; D005466:Fluorocarbons
D017341:Etanidazole; D005947:Glucose; D006845:Hydrocarbons, Fluorinated; D011838:Radiation-Sensitizing Agents; C096011:2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide; D005466:Fluorocarbons